JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorHealthcare

518.99 -0.92

Buy Sell

Overview

Share price change

24h

Current

Min

514.23

Max

527.83

Key metrics
By Trading Economics
Income	56M -59M
Sales	34M 321M
Profit margin	-18.243
Employees	915
EBITDA	56M -50M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+29.91% upside

Dividends
By Dow Jones
Next Earnings	6 maj 2026

Market Stats
By TradingEconomics
Market Cap	1.5B 12B
Previous open	519.91
Previous close	518.99

News Sentiment

By Acuity

40%

60%

135 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 kwi 2026, 23:15 UTC

Major News Events

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 kwi 2026, 23:08 UTC

Earnings

Major Market Movers

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 kwi 2026, 23:58 UTC

Earnings

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 kwi 2026, 23:58 UTC

Earnings

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 kwi 2026, 23:56 UTC

Earnings

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 kwi 2026, 23:56 UTC

Earnings

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 kwi 2026, 23:48 UTC

Market Talk

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 kwi 2026, 23:42 UTC

Market Talk

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 kwi 2026, 23:34 UTC

Market Talk

Major News Events

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 kwi 2026, 23:30 UTC

Market Talk

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 kwi 2026, 23:08 UTC

Market Talk

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 kwi 2026, 23:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 kwi 2026, 23:02 UTC

Market Talk

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 kwi 2026, 22:42 UTC

Market Talk

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 kwi 2026, 22:10 UTC

Earnings

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 kwi 2026, 22:09 UTC

Earnings

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 kwi 2026, 22:09 UTC

Earnings

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 kwi 2026, 22:09 UTC

Earnings

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 kwi 2026, 21:56 UTC

Earnings

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 kwi 2026, 21:55 UTC

Earnings

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 kwi 2026, 21:55 UTC

Earnings

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 kwi 2026, 21:44 UTC

Earnings

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 kwi 2026, 21:43 UTC

Earnings

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 kwi 2026, 21:41 UTC

Earnings

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 kwi 2026, 21:41 UTC

Earnings

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 kwi 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

27 kwi 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

27 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27 kwi 2026, 20:39 UTC

Earnings

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

29.91% upside

12 Months Forecast

Average 665.67 USD 29.91%

High 964 USD

Low 529 USD

Based on 7 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

135 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.